A diterpenoid compound and its application

The preparation of salicylene via biosynthesis has solved the problems of source and synthesis of salicylene compounds, enabled the development of antitumor drugs, provided key precursors and derivatives, and reduced the risk of environmental pollution.

CN119019216BActive Publication Date: 2026-11-10INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310611383.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-05-26
Publication Date
2026-11-10
Estimated Expiration
2043-05-26

AI Technical Summary

Technical Problem

The limited sources and difficult synthesis of cephalotaxane diterpenoids, coupled with the environmental pollution risks associated with their chemical synthesis, restrict their drug development and application.

Method used

Through a biosynthetic pathway, specific diterpenoid synthases catalyze the generation of geraniol-geraniol pyrophosphate into the diterpenoid nucleus compound cephalotene. Diterpenoid derivatives are then prepared via enzymatic reactions and molecular biology methods, followed by subsequent modifications using chemical synthesis methods.

Benefits of technology

This study provides key biosynthetic precursors for cephalotaxane diterpenoids, enabling the preparation of diterpenoid derivatives with antitumor activity for the development of novel antitumor drugs. This approach solves the challenges of sourcing and synthesis, and reduces the risk of environmental pollution.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119019216B_ABST
    Figure CN119019216B_ABST
Patent Text Reader

Abstract

This invention belongs to the field of natural product chemistry and relates to a novel diterpenoid compound having the structure shown in Formula I, named cephalotene. The compound provided by this invention has a core structure representing cephalotene diterpenoids, such as hainan cephalotene lactone, and serves as a common key precursor in the biosynthesis of cephalotene diterpenoids, providing raw materials / intermediates for obtaining hainan cephalotene lactone and other cephalotene diterpenoids. Furthermore, derivatization of this diterpenoid compound can yield various compounds with human tumor cell cytotoxic activity, which hold promise for development into antitumor drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical fields:

[0001] This invention belongs to the field of natural product chemistry, and specifically relates to a new diterpenoid compound and its applications. Technical background:

[0002] Harringtonolide (also known as hainanolide) is a diterpenoid compound with a complex structure of 6 / 6 / 5 / 7 tetracyclic rigid skeleton and high oxidation, discovered in the 1870s from plants of the Cephalotaxus genus. It includes a cycloheptatrienone structural unit and contains multiple chiral centers. It has antitumor, anti-inflammatory and antiviral activities (Buta JG, Flippen JL, Lusby W R. Harringtonolide, a plant growth inhibitory ytropone from Cephalotaxus harringtonia (Forbes) K. Koch. Journal of Organic Chemistry, 1978, 43(5), 1002-1003. Sun Nanjun, Xue Zhi, Liang Xiaotian, et al. Study on the structure of the new anticancer active ingredient, harringtonolide (Hainanolide). Acta Pharmaceutica Sinica, 1979(1). Ni L, Zhong XH, Chen XJ, Zhang BJ, Bao MF, Cai X H. Bioactive norditerpenoids from Cephalotaxus fortuneivar. alpina and C. lanceolata. Phytochemistry, 2018, 151, 50-60. To date, more than 80 compounds of this class have been reported. Figure 1These are collectively referred to as cephalotane-type diterpenoids (Jiang CY, Xue JJ, Yuan YZ, Li YZ, Zhao CX, Jing QX, Zhang X, Yang MY, Han T, Bai J, Li ZL, Li DH, Hua H M. Progress in structure, synthesis and biological activity of natural cephalotane diterpenoids. Phytochemistry, 2021, 192, 112939. Ge ZP, Zhou B, Zimbres FM, Cassera MB, Zhao JX, Yue JM. Cephalotane-Type Norditerpenoids from Cephalotaxus fortuneivar. alpina. Chinese Journal of Chemistry, 2022, 40(10), 1177-1184.).

[0003] Currently, cephalotaxane diterpenoids have only been found in plants of the genus Cephalotaxus, resulting in limited sources and low abundance. Although total chemical synthesis of these compounds has been reported, their complex structures and multiple chiral centers make synthesis difficult, time-consuming, and yield-low, thus limiting their commercial application. Furthermore, chemical synthesis often involves the use of toxic reagents, causing environmental pollution and further restricting their applications. (Xu L, Wang C, Gao Z, Zhao YM. Total Synthesis of (±)-cephanolides B and C via a Palladium-catalyzed cascade cyclization and late-stage sp3 C–H bond oxidation. Journal of American Chemical Society, 2018, 140, 5653-5658. Zhang H, He H, Gao S. Asymmetric total synthesis of cephanolideA.Angewandte Chemie International Edition,2020,59,20417-20422.Zhang H,He H,Gao S.Asymmetric total synthesis of cephanolide B.Organic Chemistry Frontier,2021,8,555-559.Haider M,Sennari G,Eggert A,Sarpong R.Total synthesis of theCephalotaxus norditerpenoids(±)-cephanolides A–D.Journal of AmericanChemical Society, 2021, 143, 2710-2715. Ao Q, Zhang HJ, Zheng J, Chen X, ZhaiH. Asymmetric total synthesis of (+)-mannolide C. Angewandte ChemieInternational Edition, 2021, 60, 21267-21271. Ren Z, Sun Z, Li Y, Fan X.Total synthesis of(+)-3-deoxyfortalpinoid F,(+)-fortalpinoid A,and(+)-cephinoid H.Angewandte Chemie International Edition, 2021, 60, 18572-18576. Li A, He Z, Liu B, Yang Z, Zhang Z. Stereoselective synthesis of (±)-cephanolideB. Organic Letters, 2021, 23, 9237-9240.). .

[0004] In summary, the limited availability of these compounds restricts their development and application as drugs. Biosynthesis can provide an effective means to address this issue; however, no research on their biosynthesis has been reported to date. The biosynthesis of these compounds uses geraniylgeraniyl pyrophosphate (GGPP) as a precursor, catalyzed by diterpene synthases to generate a diterpene core compound, which is then catalyzed by multiple post-modification enzymes to generate Hainan torreya lactone and its analogues. Currently, no diterpene core compounds of this class of compounds have been reported.

[0005] Therefore, the discovery and preparation of key precursor diterpenoid core compounds for the biosynthesis of cephalotaxine diterpenoids such as Hainan cephalotaxine lactone will provide raw materials / intermediates for the biosynthesis of cephalotaxine diterpenoids such as Hainan cephalotaxine lactone with anti-tumor and other medicinal values, and has potential application value. Summary of the Invention

[0006] In a first aspect, the present invention provides a novel diterpenoid compound having the structure shown in Formula I:

[0007]

[0008] The compound provided by this invention has a core structure representing cephalotene diterpenoids, such as hainan cephalotene lactone, and is a key precursor in the biosynthesis of cephalotene diterpenoids. This compound is named cephalotene in this invention.

[0009] The compounds provided by this invention can be obtained by enzymatic reaction using geraniylgeraniyl pyrophosphate (GGPP) as a substrate and a specific diterpenoid synthase. The diterpenoid synthase has the amino acid sequence shown in SEQ ID NO:1, or has an amino acid sequence that is at least 90% identical to the amino acid sequence shown in SEQ ID NO:1 and has catalytic activity for the formation of diterpenoid compounds. It can also be a truncated form (e.g., with the signal peptide removed) of the diterpenoid synthase having the above-mentioned amino acid sequence. Based on the determination of the substrate and the amino acid sequence of the diterpenoid synthase, the compounds can be produced by bio-fermentation and using conventional techniques in the art, such as molecular biology, biochemistry, and organic chemistry.

[0010] Secondly, the present invention provides the use of compounds having the structure shown in Formula I in the preparation of diterpenoid derivatives, said compounds being used as raw materials for the preparation of diterpenoid derivatives.

[0011] The diterpenoid derivatives described in this invention can be natural products isolated from plants, preferably from plants of the Cephalotane genus, including all cephalotane-type diterpenoids reported in the literature (Jiang CY, Xue JJ, Yuan YZ, Li YZ, Zhao CX, Jing QX, Zhang X, Yang MY, Han T, Bai J, Li ZL, Li DH, Hua H M. Progress in structure, synthesis and biological activity of natural cephalotane diterpenoids. Phytochemistry, 2021, 192, 112939) and the literature (Ge ZP, Zhou B, Zimbres FM, Cassera MB, Zhao JX, Yue JM. Cephalotane-Type Norditerpenoids from Cephalotaxus fortuneivar. alpina. Chinese Journal of Chemistry, 2022, 40(10), 1177-1184). Diterpenoids, such as Hainan torreya lactone, also include other unreported natural diterpenoids with a thiamethoxam core structure.

[0012] The diterpenoid derivatives described in this invention can also be non-natural compounds artificially synthesized from compounds as shown in Formula I, such as those that have undergone monohydroxylation or dihydroxylation based on the structure shown in Formula I.

[0013] The diterpenoid derivatives described in this invention may have a carbon skeleton structure as shown in Formula I. In other diterpenoid derivatives, the carbon skeleton may undergo carbon reduction (e.g., demethylation), carbon-carbon bond breaking, carbon chain shifting, or skeleton rearrangement based on the structure shown in Formula I.

[0014] The diterpenoid derivatives described in this invention can undergo one or more of the following derivatizations based on their carbon skeleton: hydroxylation, carbonylation, carboxylation, esterification, epoxidation, hydrogen removal, aromatization, glycosylation, methylation, acylation, isopentenylation, reduction, etc.

[0015] The specific application of this invention can be the preparation of diterpenoid derivatives using the compound shown in Formula I as a raw material and employing chemical synthesis and / or biosynthesis methods.

[0016] The chemical synthesis method described in this invention can be carried out using known principles, raw materials, and reaction conditions in the field of organic chemistry.

[0017] The biosynthetic method of this invention uses the compound shown in Formula I as a substrate to carry out an enzyme-catalyzed reaction. The enzyme used in the enzyme-catalyzed reaction can be selected from: oxidases, reductases, glycosyltransferases, methyltransferases, acyltransferases, isopentenyltransferases, etc. Specifically, the oxidase can be selected from dehydrogenases, monooxygenases (such as cytochrome P450 enzymes), or dioxygenases (α-ketoglutarate-dependent dioxygenases).

[0018] The enzyme-catalyzed reaction can be carried out using a single enzyme, a combination of multiple enzymes, or through synthetic biology techniques and design concepts. The combination of multiple enzymes can be a combination of enzymes with different catalytic principles and types, such as a combination of oxidase and glycosyltransferase, oxidase and methyltransferase, or oxidase and acyltransferase; it can also be a combination of multiple enzymes with the same catalytic principle, such as a combination of multiple enzymes from different subfamilies of cytochrome P450 enzymes, or a combination of multiple enzymes belonging to the same subfamily of cytochrome P450 enzymes but with different primary structures. The synthetic biology techniques and design concepts can utilize different synthetic elements, devices, and modules to construct artificial pathways in microorganisms (such as *Escherichia coli* and *Saccharomyces cerevisiae*), plants (such as *Nicotiana benthamiana*), and animal cells (such as insect cells), and utilize cell factories for biosynthesis.

[0019] As is well known in the art, the general pathway for the biosynthesis of diterpenoid natural products is as follows: diterpenoid synthase catalyzes GGPP cyclization to generate diterpenoid skeleton compounds, followed by a series of post-modifications on the skeleton compounds to generate diverse derivatives. Taking typical diterpenoid compounds, taxanes, as an example: the first directed reaction step in the biosynthetic pathway of this class of compounds is GGPP cyclization catalyzed by taxadiene synthase, which generates the unique skeleton structure of taxanes, "taxane-4(5),11(12)-diene"; the downstream pathway after the formation of the core skeleton includes further modifications occurring at multiple sites on the core skeleton, including hydroxylation, acylation, carbonylation, propylene oxide formation, side chain assembly, etc., ultimately generating a series of taxane derivatives, including paclitaxel. Therefore, those skilled in the art can understand that, based on the triharbine diterpenoid core structure shown in Formula I provided by this invention, conventional biosynthetic methods can be used to perform a series of post-modifications with enzymes of specific functions to obtain triharbine diterpenoid derivatives with corresponding functional groups or derived structures.

[0020] Thirdly, the present invention provides the use of compounds having the structure shown in Formula I or their diterpenoid derivatives in the preparation of antitumor drugs.

[0021] The diterpenoid derivatives described in this invention can be natural products isolated from plants, preferably from plants of the Cephalotane genus, including all cephalotane-type diterpenoids reported in the literature (Jiang CY, Xue JJ, Yuan YZ, Li YZ, Zhao CX, Jing QX, Zhang X, Yang MY, Han T, Bai J, Li ZL, Li DH, Hua H M. Progress in structure, synthesis and biological activity of natural cephalotane diterpenoids. Phytochemistry, 2021, 192, 112939) and the literature (Ge ZP, Zhou B, Zimbres FM, Cassera MB, Zhao JX, Yue JM. Cephalotane-Type Norditerpenoids from Cephalotaxus fortuneivar. alpina. Chinese Journal of Chemistry, 2022, 40(10), 1177-1184). Diterpenoids, such as Hainan torreya lactone, also include other unreported natural diterpenoids with a thiamethoxam core structure. The diterpenoid derivatives described in this invention can also be non-natural compounds artificially synthesized from compounds shown in Formula I, such as those obtained by monohydroxylation or dihydroxylation based on the structure shown in Formula I.

[0022] The diterpenoid derivatives described in this invention may have a carbon skeleton structure as shown in Formula I. In other diterpenoid derivatives, the carbon skeleton may undergo carbon reduction (e.g., demethylation), carbon-carbon bond breaking, carbon chain shifting, or skeleton rearrangement based on the structure shown in Formula I.

[0023] The diterpenoid derivatives described in this invention can undergo one or more of the following derivatizations based on their carbon skeleton: hydroxylation, carbonylation, carboxylation, esterification, epoxidation, hydrogen removal, aromatization, glycosylation, methylation, acylation, isopentenylation, reduction, etc.

[0024] The antitumor drugs described in this invention can be drugs that have cytotoxic activity against human cancer cells such as liver cancer, gastric cancer, colon cancer, and / or cervical cancer. Furthermore, numerous publications (such as Jiang CY, Xue JJ, Yuan YZ, Li YZ, Zhao CX, Jing QX, Zhang X, Yang MY, Han T, Bai J, Li ZL, Li DH, Hua H M. Progress in structure, synthesis and biological activity of natural cephalotanediterpenoids. Phytochemistry, 2021, 192, 112939, etc.) have clearly reported the antitumor activity of various natural derivatives of the compounds shown in Formula I.

[0025] Supplementary Explanation

[0026] Unless otherwise stated, the technical terms used herein have the same meanings as commonly understood by one of ordinary skill in the art. This invention may also be practiced using any methods and materials similar to or equivalent to those described herein. While specific embodiments and preferred methods and materials are described herein, they do not impose any limitation on the invention.

[0027] Beneficial technical effects

[0028] The compounds provided by this invention are based on the core structure of cephalotaxine diterpenoids, represented by hainan cephalotaxine lactone. These structures serve as key common precursors in the biosynthesis of cephalotaxine diterpenoids, providing raw materials / intermediates for obtaining cephalotaxine diterpenoids such as hainan cephalotaxine lactone through biosynthesis and / or chemical synthesis, as well as a combination of both. Furthermore, these diterpenoid compounds and their derivatives exhibit cytotoxic activity against human tumor cells, including liver cancer, gastric cancer, colon cancer, and cervical cancer, and hold promise for development into novel antitumor drugs. Attached Figure Description

[0029] Figure 1 Representative 6 / 6 / 5 / 7 tetracyclic skeleton cephalotaxine diterpenoids in Cephalotaxus species;

[0030] Figure 2 a) GC-MS analysis spectrum of salicylene; b) Gas chromatogram of salicylene (peak C); c) EI-MS mass spectrum of salicylene. Detailed Implementation

[0031] The following embodiments are provided to further illustrate various aspects of the present invention. These embodiments are non-limiting and should not be construed as limiting any aspect of the invention. The scope of protection of the present invention is limited only by the claims. Various modifications and improvements can be made to various aspects of the present invention without departing from the scope of the claims, and these modifications and improvements also fall within the scope of protection of the present invention. For example, replacing the promoters and expression vectors used in the embodiments with other promoters and expression vectors commonly used in the art is something that those skilled in the art can understand and implement.

[0032] Additionally, it should be noted that, unless otherwise specified, all materials and reagents used in the following embodiments are commonly used in the art and can be obtained through conventional commercial means; all methods used are conventional methods known to those skilled in the art.

[0033] Example 1: Cloning of the CsCTS gene

[0034] 1. Extraction of total RNA and synthesis of cDNA first strand

[0035] Select an appropriate amount of Torreya grandis stems and leaves as material, quickly transfer them to a mortar pre-cooled with liquid nitrogen, and grind them thoroughly into powder; transfer the powdered sample to a centrifuge tube, add 500 μL Buffer RCL / 100 mg tissue (EZNA) TM The plant RNA kit was used to homogenize the RNA using a vortex mixer and repeatedly pipette-mixed. The mixture was incubated at 55°C for 3 min, centrifuged at 15,000 g for 5 min, and the supernatant was transferred to a filter column and centrifuged at 14,000 g for 2 min. An equal volume of Buffer RCB was added to the filtrate, and the column was inverted 5-10 times. The liquid was transferred to an RNA adsorption column and centrifuged at 10,000 g for 1 min. The filtrate was discarded, and 400 μL of RWCwash Buffer was added to the adsorption column. The column was centrifuged at 10,000 g for 1 min. After the adsorption column was air-dried at room temperature, it was eluted with 50 μL of ddH2O to obtain total RNA. The integrity of the total RNA was assessed by 1.0% non-denaturing agarose gel electrophoresis, and the OD was measured using a UV spectrophotometer. 260 / OD 280 Ratio and RNA concentration. Using SMARTer. TM The RACE cDNA amplification kit (Clontech, USA) synthesizes the first strand of cDNA.

[0036] 2. PCR amplification of the target gene fragment

[0037] Based on the transcriptome information of *Cephalotaxus fortunei*, specific primer pairs (SEQ ID NO.3, SEQ ID NO.4) for the candidate gene CsCTS (amino acid sequence as shown in SEQ ID NO.1, nucleotide sequence as shown in SEQ ID NO.2) were designed. PCR amplification was performed using KOD DNA Polymerase to obtain the full-length CsCTS gene. The PCR product (target gene fragment) was recovered from the gel, ligated into the pEASY-blunt vector, transformed into Trans1-T1 competent cells, screened by colony PCR, and positive clones were sent for sequencing after shaking to confirm the sequence information of the candidate gene.

[0038] 2.1 PCR reaction system

[0039]

[0040]

[0041] 2.2 PCR Cycle

[0042] 1) 94℃ 2min; 2) 98℃ 10sec; 3) 58℃ 15sec; 4) 68℃ 2min;

[0043] 5) 2) 35 cycles; 6) 68℃ for 5 min; 7) Hold at 10℃.

[0044] Example 2: Expression, recombinase isolation, purification and functional identification of CsCTS gene

[0045] 1. Construction, recombinase induction, and detection of Rosetta-pET28a-CsCTS recombinant expression strain

[0046] The pET-28a(+) vector contains a strong "T7" promoter and a "T7" translation initiation signal. The vector contains His-tagged protein sequences in both the N-terminal and C-terminal. In addition, the vector contains several commonly used polyclonal restriction enzyme sites, allowing for the addition of His tags to the N-terminal or C-terminal of the target protein for fusion expression as needed.

[0047] Based on the gene sequences flanking the multiple cloning site of the pET28a(+) vector, primers containing 17 bp homologous arms (SEQ ID NO. 5, SEQ ID NO. 6) were designed. Homologous arms were introduced into the N-terminus and C-terminus of the target gene coding sequence (CDS) using PCR, and the PCR products were recovered via gel electrophoresis. The target gene was ligated to the linearized pET28a(+) vector using homologous recombinase to construct the recombinant plasmid pET28a-CsCTS. This plasmid was transformed into *E. coli* (Trans1 T1) cloning host, and positive transformants were screened by PCR. Sequencing was then used to verify the correctness of the reading frame. Transformants with correct sequencing were amplified and cultured, plasmids were extracted, and transformed into *E. coli* Rosetta competent cells. Positive clones were screened by PCR. Positive transformants were stored in 15% glycerol at -80°C.

[0048] The steps for recombinase induction expression, crude enzyme extraction, and detection are as follows: 1) Positive transformants with correct sequences, as identified by sequencing, were inoculated into LB medium containing both kanamycin (resistance carried by pET-28a vector) and chloramphenicol (resistance carried by Rosetta host bacteria), and cultured at 37℃ and 200 rpm for 12 h with shaking; 2) The activated seed culture was then inoculated into LB medium (containing kanamycin) at a ratio of 100:1. + Chloramphenicol + 1) Use 250mL Erlenmeyer flasks for the culture medium, with each flask containing 50mL of liquid (for scale-up experiments, use 500mL Erlenmeyer flasks, with each flask containing 200mL of liquid); 2) Incubate at 37℃ and 200rpm until OD reaches 500mL. 600 ≈0.6, add IPTG to each culture bottle to a final concentration of 0.2mM; induce the expression of the target enzyme at 18℃ and 200rpm; 4) after 20h of induction culture, collect the cells, centrifuge at 8,000g for 5min, discard the supernatant, and wash the cells with ddH2O 1–2 times; 5) add 3mL / g protein extraction buffer (25mM MOPS, 1mM DTT, 10% v / v glycerol, 300mM NaCl, 1mM PMSF, pH 6.8) to the cells, and vortex to resuspend the precipitate; 6) place the centrifuge tube in an ice bath and sonicate for 15min (130w, 3s / 3s), and centrifuge at 15,000g for 30min at 4℃ to collect the supernatant, which is the crude enzyme solution.

[0049] 2. Isolation and purification of CsCTS recombinase

[0050] The recombinant enzyme was expressed and purified using the Rosetta-pET28a-CsCTS recombinant expression strain. The target gene was fused with a 6×His·tag for expression. The His-tag-containing fusion protein was isolated and purified using a Ni-TED 6FF (Fast Flow resin) pre-packed column (Shanghai Sangon Biotech Co., Ltd.) affinity chromatography column and PD-10 Desalting Columns (GE Healthcare). The specific steps are as follows:

[0051] 2.1 Preparation of buffer solution

[0052] 1) Binding buffer: 25mM MOPS buffer, 10% (v / v) glycerol, 300mM NaCl, pH 6.8;

[0053] 2) elution buffer: 25mM MOPS elution solution, 300mM NaCl, 10% (v / v) glycerol, 500mM imidazole, pH 6.8;

[0054] 3) Desalting buffer: 50mM Tris-HCl, 1mM DTT, 1.5% glycerol, 50mM NaCl, 2.5mMgCl2;

[0055] 4), lysis buffer: binding buffer+1mM PMSF, pH 6.8.

[0056] 2.2 Pretreatment of Ni-TED 6FF pre-packed affinity chromatography column

[0057] Select an appropriate affinity chromatography column according to the ratio that 1 mL of Ni-TED 6FF column bed can bind 2 L of protein expressed by recombinant bacterial culture. Elute with 10 column volumes of ddH2O, binding buffer, and elution buffer in sequence, and finally equilibrate the chromatography column with binding buffer.

[0058] 2.3 Preparation and loading of CsCTS recombinase crude extract

[0059] The recombinant strain culture and protein induction expression steps are described in Part 1 of this embodiment. The recombinant bacteria were collected by centrifugation at 8,000g at 4°C. Lysis buffer was added to the bacterial cells at a ratio of 3 mL / g, and the precipitate was vortexed for resuspending. The mixture was then sonicated in an ice bath for 15 min (130 W, 3 s / 3 s), followed by centrifugation at 15,000g for 30 min at 4°C. The supernatant was the crude enzyme extract. The obtained crude enzyme extract was filtered through a 0.45 μm filter membrane and loaded into an affinity chromatography column at a flow rate of 1 mL / min.

[0060] 2.4 CsCTS recombinase elution

[0061] After sample loading, elute with 10 column volumes of binding buffer at a flow rate of 1 mL / min to remove contaminating proteins. Once the eluent absorbance at 280 nm approaches 0, elute the target protein. Prepare gradient elution buffers with different imidazole concentrations for the target protein: 10 mM, 20 mM, 50 mM, and 100 mM. Finally, elute with elution buffer, using 5 column volumes for each concentration gradient. Analyze each fraction using SDS-PAGE. Concentrate the high-purity fraction containing the target protein by ultrafiltration in a 30 kDa Millipore centrifuge tube.

[0062] 2.5. CsCTS recombinase desalting

[0063] The PD-10 Desalting Column was equilibrated with 10 column volumes of pre-cooled ddH2O and desalting buffer. The protein concentrate obtained by ultrafiltration was slowly loaded onto the upper layer of the desalting column. After the sample had completely entered the desalting column, it was eluted with desalting buffer and the eluent was collected. Each 1 mL fraction was collected for SDS-PAGE analysis. According to the elution principle of the PD-10 desalting column, the fractions were combined, diluted with desalting buffer to an appropriate volume, and the protein content was determined.

[0064] 3. Functional identification of CsCTS recombinase

[0065] The catalytic function of recombinant CsCTS was identified using GGPP as a substrate. The reaction system was as follows: 10 μg GGPP, 0.2 mg recombinant CsCTS protein, total reaction volume 500 μL, reaction buffer (50 mM Tris-HCl, 1 mM DTT, 1.5% glycerol, 50 mM NaCl, 2.5 mM MgCl2), reacted in a water bath at 30 °C for 12 h, and then the reaction was stopped. Extraction with n-hexane: 700 μL of n-hexane was used, vortexed for 20 s, allowed to stand for 20 s, and repeated 3 times; then, centrifuged at 15,000 g for 10 min at 4 °C, and the upper n-hexane phase was collected; after 3 extractions, the n-hexane extract phase was collected, concentrated, and diluted to 100 μL for GC-MS analysis. Figure 2 ).

[0066] Example 3: Preparation of the diterpenoid product cephalotene

[0067] 1. Construction and fermentation of Cephalotene-producing engineered bacteria

[0068] 200 ng of pIRS, 200 ng of pGG, and 200 ng of pET28a-CsCTS were co-transformed into E. coli BL21(DE3). Positive transformants, whose sequences were confirmed by sequencing, were inoculated into LB (kanamycin) culture containing the three antibiotics. + Chloramphenicol + Spectinomycin + The culture medium was incubated at 37°C with shaking at 200 rpm for 12 h. The activated seed culture was then inoculated at a ratio of 100:1 into TB (kanamycin) culture medium. + Chloramphenicol + Spectinomycin + In the culture medium, use 500mL Erlenmeyer flasks, each containing 200mL of liquid, for a total of 20L. Incubate at 37℃ for approximately 2.5 hours to allow OD to reach its target value. 600 Reduce the concentration to 0.6-0.8. After incubating at 18℃ for 1 hour, add 0.2 mM IPTG to induce induction for 72 hours.

[0069] 2. Preparation of Cephalotene (I)

[0070] The recombinant bacterial culture obtained from fermentation was centrifuged at 8,000g at 4℃ to collect the bacterial cells and bacterial solution separately. The bacterial solution was extracted three times with an equal volume of ethyl acetate and concentrated under reduced pressure to obtain an extract. The bacterial cells were extracted three times with methanol using ultrasound, the methanol phase was collected and concentrated under reduced pressure, then dispersed in water, and extracted three times with an equal volume of ethyl acetate and concentrated under reduced pressure to obtain an extract. The two extracts were combined and subjected to silica gel column chromatography, eluted with n-hexane, and detected by GC-MS to obtain the product Cephalotene. Optical rotation, UV, IR, MS, and NMR measurements were performed, and the physicochemical data are as follows:

[0071] Cephalotene (I): [α] D 20 -10.8 (c=0.50, CH₂Cl₂). EI-MS: [M] + m / z=272. UV (MeOH) λ max (logε) 203 (1.27), 240 (0.55) nm. IR ν max 2950, 2924, 2869, 1456, 1441, 1376, 1038 cm -1 . 1 ¹H NMR (CDCl₃, 600 MHz), δ H : 1.82 (2H, t, 9.6 Hz, H-1), 2.83 (m, H-2), 5.41 (d, 8.4 Hz, H-4), 1.86 (m, H-5α), 2.24 (m, H-5β), 1.36 (m, H-6α), 1.48 (m, H-6β), 1.47 (m, H-8α), 0.84 (m, H-8β), 1.26 (m, H-9α), 1.61 (dt, 14.4, 3.6, H-9β), 1.80 (m, H-11), 1.15 (m, H-12α), 0.95 (m, H-12β), 1.46 (m, H-13α), 1.79 (m, H-13β), 2.30 (m, H-14), 1.96 (2H, m, H-15, H-16), 0.86 (3H, s, H-17), 0.74 (3H, d, 6.6, H-18), 0.97 (3H, s, H-19), 1.66 (3H, s, H-20). 13 ¹³C NMR (CDCl₃, 150 MHz), δ C : 37.8 (C-1), 43.5 (C-2), 141.0 (C-3), 125.8 (C-4), 22.9 (C-5), 43.2 (C-6), 33.8 (C-7), 31.6 (C-8), 32.0 (C-9), 34.4 (C-10), 29.4 (C-11), 26.0 (C-12), 24.1 (C-13), 34.3 (C-14), 48.2 (C-15), 53.7 (C-16), 26.5 (C-17), 16.6 (C-18), 26.4 (C-19), 24.5 (C-20).

[0072] Example 4: Cephalotene derivative 3,4-Dihydroxycephalotene (Ia) Preparation

[0073] Dissolve 195.6 mg cephalotene (719.7 μmol, 1.0 equiv) in a mixed solvent of 3.75 mL t-BuOH and 3.75 mL H2O. Add 707.5 mg K3Fe(CN)6 (2159.1 μmol, 3.0 equiv), 297.5 mg K2CO3 (2159.1 μmol, 3.0 equiv), 67.5 mg MeSO2NH2 (719.7 μmol, 1.0 equiv), 25.0 mg K2OsO2(OH)4 (67.8 μmol, 10.0 mol%), and 100.0 mg (DHQD)2PHAL (128.5 μmol, 0.20 mol%). Stir the mixture at room temperature (23 °C) for 2 days (monitor the reaction process in real time). Add excess Na2S2O3 and stir for 10 min to terminate the reaction. The reaction solution was extracted three times with CH2Cl2. The combined extracts were dried over Na2SO4, concentrated to dryness under reduced pressure, dissolved in ethyl acetate, evaporated to dryness, and weighed. The solution was then subjected to silica gel column chromatography, with the eluent being petroleum ether:ethyl acetate = 4 / 1. The reaction product was detected by GC-MS, and optical rotation, UV, IR, MS, and NMR were performed. The prepared dihydroxylated product was crystallized under a hexane:ethyl acetate ratio of 10:1. The obtained single crystals were analyzed by X-ray single-crystal diffraction, and the data are as follows:

[0074] 3,4-Dihydroxy-cephalotene (Ia):[α] D 20 -21.8 (c=0.44, MeOH); EI-MS: m / z=306[M] + IRv max 3406,2949,2925,2871,1642,1466,1375,1080cm -1 . 1 HNMR (CDCl3, 600MHz), δ H:2.18(m,H-1α),1.72(m,H-1β),2.42(m,H-2),3.61(dd,5.2,1.6Hz,H-4),1.65(m,H-5α),1.76(m,H-5β),0.95(m,H-6α),2.00(m,H-6β),1.21(m,H-8α),1.07(m,H-8β),1.19(m,H-9α),1.48(m,H-9β),1.66(m,H-11),1.73(m,H-12α),1.21(m,H-12β),1.53(m,H-13α),1.73(m,H-13β),1.72(m,H-14),1.87(t,8.0,H-15),1.51(m,H-16),0.84(3H,s,H-17),0.72(3H,d,6.6,H-18),0.93(3H,s,H-19),1.11(3H,s,H-20). 13 C NMR(CDCl3,150MHz),δ C :37.2(C-1),43.1(C-2),78.1(C-3),75.5(C-4),24.6(C-5),32.3(C-6),33.2(C-7),33.7(C-8),31.6(C-9),34.0(C-10),30.8(C-11),25.8(C-12),22.6(C-13),33.7(C-14),48.7(C-15),50.7(C-16),24.6(C-17),16.1(C-18),28.9(C-19),20.6(C-20). Single crystal data:C 20 H 34 O2,0.375(H2O)(M=313.23g / mol):triclinic,space group P1(no.1), α=89.7661(4)°,β=83.0676(4)°,γ=80.7903(4)°, Z=8,T=100.00(10)K,μ(Cu Kα)=0.553mm -1 ,Dcalc=1.132g / cm 3 ,128486reflections measured(7.436°≤2Θ≤144.252°),27337unique(R int =0.0312,R sigma=0.0260)which were used in all calculations.Thefinal R1 was 0.0364(I>2σ(I))and wR2 was 0.0941(all data).

[0075] The structure of 3,4-dihydroxysharpenene (Ia) is shown below:

[0076]

[0077] Example 5: Study on the antitumor activity of salicylene and 3,4-dihydroxysalicylene

[0078] Hepatocellular carcinoma (Huh7), gastric cancer (BGC823), colon cancer (HCT-8), and cervical cancer (HeLa) cells in logarithmic growth phase were digested with 0.25% trypsin-EDTA and prepared into single-cell suspensions of a certain concentration. Based on the difference in cell growth rate, 1500 cells per well were seeded into 96-well plates, and 100 μl of cell suspension was added to each well. 24 hours later, fresh culture medium containing different concentrations of the drug and corresponding solvent controls was added. 100 μl of DMSO (final concentration <0.1%) was added to each well. Five dose groups were set up for each test compound, with paclitaxel as the positive control. Each group had at least three parallel wells. After incubation at 37°C for 96 hours, the supernatant was discarded. 100 μl of freshly prepared serum-free culture medium containing 0.5 mg / ml MTT was added to each well. After incubation for another 4 hours, the supernatant was discarded. 150 μl of DMSO was added to each well to dissolve the MTT precipitate. After mixing with a micro-shaker, the optical density (OD) was measured using a microplate reader at a reference wavelength of 450 nm and a detection wavelength of 570 nm. Tumor cells treated with the solvent control were used as the control group. The inhibitory rate of the drug on tumor cells was calculated, and the IC50 was calculated according to the intermediate-efficacy equation. 50 value.

[0079] The results (Table 1) showed that compounds I and Ia had inhibitory activity on the proliferation of human hepatocellular carcinoma cell line Huh7, human gastric carcinoma cell line BGC823, human colon cancer cell line HCT-8, and human cervical cancer cell line HeLa, respectively.

[0080] Table 1. In vitro cytotoxic activities of compounds I and Ia

[0081]

Claims

1. A compound, characterized in that, It has a structure as shown in Equation I: 。 2. The use of the compound of claim 1 in the preparation of 3,4-dihydroxysalicylic acid, wherein the structural formula of 3,4-dihydroxysalicylic acid is: 。 3. The use of the compound of claim 1 in the preparation of a drug for inhibiting liver cancer cells, gastric cancer cells, colon cancer cells or cervical cancer cells.

4. The use of 3,4-dihydroxyharzeneene as described in claim 2 in the preparation of drugs for inhibiting liver cancer cells, gastric cancer cells, colon cancer cells or cervical cancer cells.